ACE2 and COVID-19: Even though human ACE2 (hACE2), which is the entry receptor for SARS-CoV-2, has been well established, the contribution of the enzymatic functions of ACE2 to the pathogenesis of COVID-19-related lung injury has been a matter of debate [45].